Journal of Clinical Oncology, Vol 6, 142-146, Copyright © 1988 by American Society of Clinical Oncology
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study
JD Hines, MH Zakem, DJ Adelstein and YM Rustum
Division of Hematology and Oncology, Cleveland Metropolitan General Hospital/Case Western Reserve University School of Medicine, OH 44109.
Thirty-one evaluable patients with measurable advanced colorectal carcinoma
were entered into a pilot study that used weekly fluorouracil (5-FU) at the
dose of 600 mg/m2 by bolus infusion administered midway during a two-hour
leucovorin calcium infusion of 500 mg/m2. This regimen was repeated weekly
for six doses. Twenty-seven of these patients (87%) were considered to be
refractory to prior 5-FU therapy and four (13%) were previously untreated.
All 31 patients successfully completed at least one 6-week cycle of this
regimen with acceptable toxicity. The combined complete (CR) and partial
response (PR) rate was 45% with another 25% of patients remaining stable.
The 95% confidence levels for the responding patients are 27.6% and 62.7%,
respectively. The remaining 30% of the patients had all received prior 5-FU
therapy and progressed. All of the responding patients and 80% of the
patients with stable disease received two or more cycles of this regimen
after a 3- to 4-week interval off therapy. The median time to disease
progression was 16.1 months for responding patients and 6.7 months for
those patients with stable disease. The median survival for the responders
was 20.6 months and for those with stable disease 9.8 months. The median
survival for the nonresponding patients was 3.9 months. Toxicity included
diarrhea in 70% of patients, skin rash (erythema) in 10%, stomatitis in
15%, nausea and vomiting in 25%, and myelosuppression in 10%. This study
confirms and extends previous observations that demonstrate the improved
efficacy of 5-FU when used with high-dose leucovorin in advanced colorectal
carcinoma.